These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33589226)

  • 1. Lipid Clinics Network. Rationale and design of the EAS global project.
    Alieva AS; Tokgözoğlu L; Ray KK; Catapano AL
    Atheroscler Suppl; 2020 Dec; 42():e6-e8. PubMed ID: 33589226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ECS guidelines 2016 - dyslipidaemias].
    Sinning D; Landmesser U
    Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new joint EAS/ESC guidelines for the management of dyslipidaemias.
    Catapano AL; Chapman J; Wiklund O; Taskinen MR
    Atherosclerosis; 2011 Jul; 217(1):1. PubMed ID: 21722901
    [No Abstract]   [Full Text] [Related]  

  • 4. [2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: What is new?].
    Kayıkçıoğlu M; Tokgözoğlu L
    Turk Kardiyol Dern Ars; 2017 Mar; 45(2):109-112. PubMed ID: 28424431
    [No Abstract]   [Full Text] [Related]  

  • 5. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman M; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D; ;
    Atherosclerosis; 2011 Jul; 217(1):3-46. PubMed ID: 21882396
    [No Abstract]   [Full Text] [Related]  

  • 6. [Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidelines related to the diagnostics and treatment of dyslipidemias issued in 2011].
    Soška V; Vaverková H; Vráblík M; Bláha V; Cífková R; Freiberger T; Kraml P; Piťha J; Rosolová H; Stulc T; Urbanová Z
    Vnitr Lek; 2013 Feb; 59(2):120-6. PubMed ID: 23461401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of dyslipidaemias: The New 2019 ESC/EAS-Guideline].
    Vogt A; Weingärtner O
    Dtsch Med Wochenschr; 2021 Jan; 146(2):75-84. PubMed ID: 33465803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D;
    Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445
    [No Abstract]   [Full Text] [Related]  

  • 10. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
    Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment].
    Arai H
    Rinsho Byori; 2014 Sep; 62(9):878-83. PubMed ID: 27526533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Present Execution of and Problems with Clinical Lipid Examination and Application of "the Japan Atherosclerotic Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012"].
    Igarashi M; Tanji Y; Nomura T; Yamaguchi H
    Rinsho Byori; 2014 Sep; 62(9):884-91. PubMed ID: 27526534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
    Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
    Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A perspective to lipid lowering therapy after ESC/EAS guidelines for the management of dyslipidaemias and the European guidelines on cardiovascular disease prevention in clinical practice].
    Ural D
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):293-7. PubMed ID: 22951844
    [No Abstract]   [Full Text] [Related]  

  • 15. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
    Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WMM; Vlachopoulos C; Wood DA; Zamorano JL; Cooney MT;
    Eur Heart J; 2016 Oct; 37(39):2999-3058. PubMed ID: 27567407
    [No Abstract]   [Full Text] [Related]  

  • 16. Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review.
    Bruckert E; Parhofer KG; Gonzalez-Juanatey JR; Nordestgaard B; Arca M; Giovas P; Ray K
    Adv Ther; 2020 May; 37(5):1724-1736. PubMed ID: 32200537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?
    Graham IM; Catapano AL
    Curr Cardiol Rep; 2017 Jun; 19(6):49. PubMed ID: 28432660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Reiner Z; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Filardi PP; Riccardi G; Storey RF; Wood D;
    Eur Heart J; 2011 Jul; 32(14):1769-818. PubMed ID: 21712404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
    Catapano AL; Averna M; Faggiano P; Novo S
    G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
    [No Abstract]   [Full Text] [Related]  

  • 20. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).
    ; Catapano AL; Graham I; De Backer G; Wiklund O; Chapman MJ; Drexel H; Hoes AW; Jennings CS; Landmesser U; Pedersen TR; Reiner Ž; Riccardi G; Taskinen MR; Tokgozoglu L; Verschuren WM; Vlachopoulos C; Wood DA; Zamorano JL
    Atherosclerosis; 2016 Oct; 253():281-344. PubMed ID: 27594540
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.